Interesting - If Remestemcel-L has greater efficacy in COVID-19 ARDS than Ruxolitinib it ‘could’ be viewed by some as a sneak peak at the expected preliminary result of the eventual GVHD results in adults in the confirmatory trial comparing the two, especially due to the similarities like cytokine storms, etc etc ?
Thanks for the article @cindyc
GLTAH
Interesting - If Remestemcel-L has greater efficacy in COVID-19...
-
- There are more pages in this discussion • 10,099 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.060(6.32%) |
Mkt cap ! $1.124B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | $1.03 | 95.0¢ | $5.238M | 5.231M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 15979 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 49129 | 21 |
View Market Depth
| Last trade - 15.05pm 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |